Pan, X. Q., Zheng, X., Shi, G., Wang, H., Ratnam, M., & Lee, R. J. (2002). Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid.Blood, 100, 594–602. Ar...
Ho-166 does provide diagnostic γ emission that can be imaged with SPECT or SPECT/CT postimplantation. In addition to allowing for more accurate assessment of absorbed dose to tumor and detection of nontarget embolization after treatment, a “scout” dose can be used in lieu of Tc-99m MAA ...
(abstract 405) show that when bendamustine was used with rituximab in the first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas, it "beat the standard in the field," he said, which is rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine [Oncovin...
Alternatively, the inhibition of the activin receptor 2B signaling (as for the receptor for myostatin) has been shown to prevent loss of muscle mass induced by folfiri or doxorubicin administration [101–104]. Interestingly, activin receptor 2B inhibition affects the production of...
Survivin (also named BIRC5) is a well-known cancer therapeutic target. Since its discovery more than two decades ago, the use of survivin as a target for cancer therapeutics has remained a central goal of survivin studies in the cancer field. Many studie
Effects of doxorubicin cancer therapy on autophagy and the ubiquitin-proteasome system in long-term cultured adult rat cardiomyocytes Cell Tissue Res., 350 (2012), pp. 361-372 CrossrefView in ScopusGoogle Scholar [184] O. Masson, A.S. Bach, D. Derocq, C. Prébois, V. Laurent-Matha, ...
Which chemotherapy drugs could be affected by pinellia? At least 20, including doxorubicin, vinblastine, vincristine, cyclophosphamide, tamoxifen and paclitaxel.8Do any of these names ring a bell? Oh, and what about your fragile cardiac patients? Perhaps you remember that in 2004 the FDA banned ...
The current standard for patients with advanced diffuse large B-cell lymphoma (DLBCL) is R-CHOP-21 (21-day rituximab-cyclophosphamidedoxorubicin- vincristine-prednisone). However, while this regimen cures approximately two-thirds of patients, a significant fraction of patients will still relapse, and...
Extracorporeal photopheresis (ECP) is an FDA-approved immunotherapy for cutaneous T-cell lymphoma, which can provide a complete response in some patients. However, it is still being determined who will respond well, and predictive biomarkers are urgently needed to target patients for timely treatment...
The reduction of doxorubicin activity was explained via this mechanism [27]. We found, with Selye, that the increased resistance after treatment with hormones, steroids, or stress was accompanied by reduced blood levels of the toxic agents [24]. This was very clear in many cases, e.g., ...